Adventist LaGrange Hospital
Click Here To Subscribe
Whats New
Newsletter Topics
Allergy
Arthritis
Asthma
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Gastrointestinal Health
Healthy Diet
Heart Disease
Integrative Medicine
Men's Health
Neurology
Orthopedics
Parenting
Pediatrics
Pregnancy
Seniors' Health
Skin Health
Stroke Rehabilitation
Weight Management
Women's Health
Women's Heart Health
E-Health Services
My Health Newsletter
My Health Reminders
My Health Reminders for Loved Ones
My Baby Expectations
My Health Links
Daily Health News
Latest News
Health Highlights
FDA Approvals
FYI
Health Information
Medline Plus
Health Assessments
Recommend These Services
About Us CareersContact Us Directions Make a Gift Find a Doctor NewsVolunteer
E-Home Feedback  
User Name: Password: Forgot Password?
Remember my username and password for future login.
 
 FDA Approvals
Return to
Daily Health Main Page.

  Ella Emergency Contraceptive Approved
 
  Intended to inhibit or delay ovulation

 

MONDAY, Aug. 16 (HealthDay News) -- The ella emergency contraceptive has been approved by the U.S. Food and Drug Administration. It's been available in Europe for more than a year under the brand name ellaOne.

To be taken within five days of contraceptive failure or unprotected intercourse, the drug is not meant to be used as a routine contraceptive, the FDA said in news release. Among a class of drugs called progesterone agonists/antagonists, it's intended to inhibit or delay ovulation.

Ella's safety and effectiveness were demonstrated in studies conducted in the United States, United Kingdom and Ireland, the agency said. The most common side effects included headache, nausea, abdominal pain, menstrual pain, fatigue and dizziness.

Women with known or suspected pregnancy or those who are breast-feeding shouldn't use ella, the FDA said.

The drug is distributed by Watson Pharma Inc., based in Morristown, N.J.

More information

The FDA has more about this approval.

 
 
   More  FDA Approvals
 
   •  Flu Vaccine for Upcoming Season Approved
  Protects against three strains predicted to be most prevalent
 
   •  Cuvposa Approved for Chronic Drooling in Children
  Primarily those with neurological disorders
 
   •  Combination Drug Approved for High Blood Pressure
  Tribenzor sanctioned for those who don't respond to other drugs
 
   •  Generic Lovenox Approved for Deep Vein Thrombosis
  A condition that could cause deadly blood clots
 
   
Health Content Provided By :